The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer.

Figures 3K–M indicate that while addition of CQ or Baf provided a modest degree of sensitization to Fulvestrant alone, in terms of delaying proliferative recovery, sensitization of the MCF7 cells to Palbociclib or the combination treatment was barely significant.

also in 875 other papers

The growth inhibitory effect of fulvestrant alone did not achieve significance, in contrast to the moderate effects in the temporal response assay; consequently, the observed effects are largely palbociclib driven.

also in 1,397 other papers